Literature DB >> 12503663

Management of opportunistic infections in pediatric HIV.

R H Merchant1, Zafar A Quadir.   

Abstract

Human immunodeficiency virus (HIV) causes a chronic infection that leads to profound immunosuppression. A hallmark of this process is the depletion of CD4+ lymphocytes, which predisposes the patient to develop a variety of opportunistic infections and certain neoplasms. The CD4+ lymphocyte count is the best validated predictor of the likelihood of developing opportunistic infections (OI). Susceptibility to OI increases as HIV induced immunosuppression becomes more severe. The management of HIV infection hence involves not only inhibiting viral replication using antiretroviral drugs, but also treating OI. This article focuses on the management of such commonly occurring OI in HIV infected patients.

Entities:  

Mesh:

Year:  2002        PMID: 12503663     DOI: 10.1007/BF02726017

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   5.319


  14 in total

1.  Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.

Authors:  K Luzuriaga; Y Bryson; P Krogstad; J Robinson; B Stechenberg; M Lamson; S Cort; J L Sullivan
Journal:  N Engl J Med       Date:  1997-05-08       Impact factor: 91.245

Review 2.  Pneumocystis carinii pneumonia: new approaches to diagnosis, treatment and prevention.

Authors:  W T Hughes
Journal:  Pediatr Infect Dis J       Date:  1991-05       Impact factor: 2.129

3.  Persistent diarrhea and fecal shedding of retroviral nucleic acids in children infected with human immunodeficiency virus.

Authors:  R H Yolken; S Li; J Perman; R Viscidi
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

4.  Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.

Authors:  R E Chaisson; P Keiser; M Pierce; W J Fessel; J Ruskin; C Lahart; C A Benson; K Meek; N Siepman; J C Craft
Journal:  AIDS       Date:  1997-03       Impact factor: 4.177

5.  The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.

Authors:  L M Mofenson; J Korelitz; W A Meyer; J Bethel; K Rich; S Pahwa; J Moye; R Nugent; J Read
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

6.  Effect of corticosteroids on survival of children with acquired immunodeficiency syndrome and Pneumocystis carinii-related respiratory failure.

Authors:  G E McLaughlin; S S Virdee; C L Schleien; B H Holzman; G B Scott
Journal:  J Pediatr       Date:  1995-05       Impact factor: 4.406

7.  Opportunistic infections occurring during highly active antiretroviral treatment.

Authors:  C Michelet; C Arvieux; C François; J M Besnier; J P Rogez; J P Breux; F Souala; C Allavena; F Raffi; M Garre; F Cartier
Journal:  AIDS       Date:  1998-10-01       Impact factor: 4.177

8.  Arteriopathy in children with acquired immune deficiency syndrome.

Authors:  V V Joshi; B Pawel; E Connor; L Sharer; J M Oleske; S Morrison; J Marin-Garcia
Journal:  Pediatr Pathol       Date:  1987

9.  Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.

Authors:  E J Abrams; J Weedon; R W Steketee; G Lambert; M Bamji; T Brown; M L Kalish; E E Schoenbaum; P A Thomas; D M Thea
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

10.  1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1995-04-28
View more
  2 in total

Review 1.  HIV-1/mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis?

Authors:  Collin R Diedrich; Joanne L Flynn
Journal:  Infect Immun       Date:  2011-01-18       Impact factor: 3.441

Review 2.  Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials.

Authors:  Henok Tadesse Ayele; Maaike S M van Mourik; Thomas P A Debray; Marc J M Bonten
Journal:  PLoS One       Date:  2015-11-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.